Procter & Gamble
PG · NYSESoap, Detergents, Cleang Preparations, Perfumes, Cosmetics · Fiscal year ends Jun 30
Procter & Gamble reported revenue of $87B in the fiscal year ended Jun 2026, up 3.3% from the year before. Operating income was $19.7B, an operating margin of 22.7%, and net income was $16B. Operating cash flow of $19.6B less capital expenditure of $4.4B left free cash flow of $15.1B. Net debt was $19.4B.
Last 5 fiscal years
Revenue and net income
Income statement
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | $80.2B | $82B | $84B | $84.3B | $87B |
| Cost of revenue | $42.2B | $42.8B | $40.8B | $41.2B | $43.4B |
| Gross profit | $38B | $39.2B | $43.2B | $43.1B | $43.7B |
| Research & development | $2B | $2B | $2B | $2.1B | $2.1B |
| Selling, general & admin | $20.2B | $21.1B | $23.3B | $22.7B | $23.9B |
| Operating income | $17.8B | $18.1B | $18.5B | $20.5B | $19.7B |
| Interest expense | $439M | $756M | $925M | $907M | $877M |
| Pre-tax income | $18B | $18.4B | $18.8B | $20.2B | $20.4B |
| Income tax | $3.2B | $3.6B | $3.8B | $4.1B | $4.2B |
| Net income | $14.7B | $14.7B | $14.9B | $16B | $16B |
| Diluted EPS | 5.81 | 5.90 | 6.02 | 6.51 | 6.62 |
| Diluted shares | 2,539M | 2,484M | 2,472M | 2,454M | 2,423M |
Balance sheet
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Cash & equivalents | $7.2B | $8.2B | $9.5B | $9.6B | $9.9B |
| Receivables | $5.1B | $5.5B | $6.1B | $6.2B | $6.1B |
| Inventory | $6.9B | $7.1B | $7B | $7.6B | $8.2B |
| Current assets | $21.7B | $22.6B | $24.7B | $25.4B | $26.2B |
| Net PP&E | $21.2B | $21.9B | $22.2B | $23.9B | $25.4B |
| Goodwill | $39.7B | $40.7B | $40.3B | $41.7B | $41.3B |
| Total assets | $117B | $121B | $122B | $125B | $127B |
| Payables | $14.9B | $14.6B | $15.4B | $15.2B | $16.3B |
| Current liabilities | $33.1B | $35.8B | $33.6B | $36.1B | $38.7B |
| Short-term debt | $3.6B | $4B | $3.8B | $5.4B | $6.5B |
| Long-term debt | $22.8B | $24.4B | $25.3B | $25B | $22.8B |
| Total liabilities | $70.4B | $73.8B | $71.8B | $72.9B | $72.2B |
| Shareholders' equity | $46.9B | $47.1B | $50.6B | $52.3B | $54.3B |
Cash flow
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Operating cash flow | $16.7B | $16.8B | $19.8B | $17.8B | $19.6B |
| Capital expenditure | $3.2B | $3.1B | $3.3B | $3.8B | $4.4B |
| Free cash flow | $13.6B | $13.8B | $16.5B | $14B | $15.1B |
| Depreciation & amortisation | $2.8B | $2.7B | $2.9B | $2.8B | $3.2B |
| Stock-based compensation | $528M | $545M | $562M | $476M | $524M |
| Acquisitions | $1.4B | $765M | $21M | $11M | $85M |
| Share buybacks | $10B | $7.4B | $5B | $6.5B | $5B |
| Dividends paid | $8.8B | $9B | $9.3B | $9.9B | $10.2B |
| Dividend per share | 3.52 | 3.68 | 3.83 | 4.08 | 4.26 |
Key ratios
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 2.3% | 2.5% | 0.3% | 3.3% |
| Operating income growth (YoY) | – | 1.8% | 2.3% | 10.3% | −3.4% |
| EPS growth (YoY) | – | 1.5% | 2.0% | 8.1% | 1.7% |
| Gross margin | 47.4% | 47.9% | 51.4% | 51.2% | 50.2% |
| Operating margin | 22.2% | 22.1% | 22.1% | 24.3% | 22.7% |
| Net margin | 18.4% | 17.9% | 17.7% | 19.0% | 18.4% |
| Return on equityBlank when equity is negative | 31.5% | 31.1% | 29.4% | 30.6% | 29.5% |
| ROCEEBIT ÷ (assets − current liabilities) | 21.2% | 21.3% | 20.9% | 22.9% | 22.5% |
| Free cash flow margin | 16.9% | 16.8% | 19.7% | 16.7% | 17.4% |
| Cash conversion (CFO ÷ net income) | 1.13x | 1.15x | 1.33x | 1.12x | 1.22x |
| Receivable days | 23 | 24 | 27 | 27 | 25 |
| Inventory days | 60 | 60 | 63 | 67 | 69 |
| Payable days | 129 | 125 | 137 | 135 | 137 |
| Interest cover | 40.6x | 24.0x | 20.0x | 22.5x | 22.5x |
| Debt ÷ equity | 0.57x | 0.60x | 0.58x | 0.58x | 0.54x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | $19.3B | $20.1B | $19.6B | $20.8B | $19.4B |
| Current ratio | 0.65x | 0.63x | 0.73x | 0.70x | 0.68x |
Recent filings
More in Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.